ArticleHealth science reports2026
Enhancing Immunotherapy in Lung Cancer: The Promise of dMMR/MSI-H Tumors and Immune Checkpoint Inhibitors.
Article in Health science reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Enhancing Immunotherapy in Lung Cancer: The Promise of dMMR/MSI-H Tumors and Immune Checkpoint Inhibitors.Health science reports · 2026Article
- Relationship between MLH1, MSH2, MSH6, and PMS2 protein expression status and clinicopathological characteristics in colorectal cancer tissues.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lung cancer remains one of the most common causes of global cancer mortality, and approximately 85% of lung cancer diagnoses are classified as non-small cell lung cancer (NSCLC). Although surgery, chemotherapy, and radiotherapy have shown varying degrees of efficacy, the results may still not consistently lead to long-term improvements in cancer-specific survival rates. Immune checkpoint inhibitors (ICIs) have fundamentally altered cancer treatment paradigms owing to their unique mechanisms of action, which involve harnessing the immune system to target and destroy cancer cells. The PD-1/PD-L1 axis represents one of the pathways for which there are numerous immunotherapeutic options, and has shown particularly strong activity against tumors with a high mutational burden. Discussion: One factor that could enhance the responsiveness of tumors to these therapies is the presence of high microsatellite instability (MSI-H) or deficient DNA mismatch repair (dMMR), which could lead to an increased mutational burden of a tumor, making it more visible to the immune system. This study will discuss newly emerging strategies targeting dMMR/MSI-H in lung cancer using immune checkpoint inhibitors, the biology of dMMR/MSI-H, evidence to date, and future directions in this space. Conclusion: Since only a minority of patients with NSCLC benefit from ICIs, it is essential and prudent to continue identifying prognostic markers, such as MSI-H/dMMR and other genomic or immune signatures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.